Grant: Collaborative Research and Development Grants
McGill University
$110,000.00
Toward the accurate prediction of adverse drug reactions and drug-drug interactions using novel MM methods and QM-derived rules
EF 2017-18
Résumé
Adverse drug reactions (ADRs) and toxicity are major causes of the high attrition rates observed in drug discovery and development programs. It has been shown that reactive metabolites produced by metabolic enzymes such as cytochrome P450s (CYPs) further react with biomolecules such as proteins, DNA or glutathione, leading to hepatotoxicity or DNA mutations causing cancer. In parallel, drug-drug interaction (DDI) is often caused by CYP inhibition by one of the co-administered drugs. Computational prediction of reactive metabolites and DDIs is a promising avenue for more successful drug discovery programs. In this context, we have developed a program, IMPACTS, which predicts the site of metabolism of drugs and the binding of drugs to CYPs. IMPACTS combines ligand reactivity rules based on pre-computed activation energies of drug sites and docking using molecular mechanics (MM) routines. We propose to carry out additional QM investigations and to develop an improved molecular mechanics approach as a continuation of our previously successful CRD grant applications with AstraZeneca (2010-2012, development of IMPACTS) then chemical computing group (2013-now). Over the last 3 years we completed proof-of-principle studies and will further develop our software to include a module for DDIs prediction and an improved version for reactive metabolites prediction, as well as a generalized and more accurate force field (FF) based on chemical principles.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
505509-2016
Name nom
Moitessier, Nicolas
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
110000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
3156
Research subject group en
Theoretical physics and chemistry
Research subject group fr
Physique et chimie théoriques
Research subject en
Quantum and/or computational chemistry
Research subject fr
Chimie quantique ou par modélisation numérique
Partie
1 & 2
Nb partie
2
Application title
Toward the accurate prediction of adverse drug reactions and drug-drug interactions using novel MM methods and QM-derived rules
Keyword
NSERC
Application summary
Adverse drug reactions (ADRs) and toxicity are major causes of the high attrition rates observed in drug discovery and development programs. It has been shown that reactive metabolites produced by metabolic enzymes such as cytochrome P450s (CYPs) further react with biomolecules such as proteins, DNA or glutathione, leading to hepatotoxicity or DNA mutations causing cancer. In parallel, drug-drug interaction (DDI) is often caused by CYP inhibition by one of the co-administered drugs. Computational prediction of reactive metabolites and DDIs is a promising avenue for more successful drug discovery programs. In this context, we have developed a program, IMPACTS, which predicts the site of metabolism of drugs and the binding of drugs to CYPs. IMPACTS combines ligand reactivity rules based on pre-computed activation energies of drug sites and docking using molecular mechanics (MM) routines. We propose to carry out additional QM investigations and to develop an improved molecular mechanics approach as a continuation of our previously successful CRD grant applications with AstraZeneca (2010-2012, development of IMPACTS) then chemical computing group (2013-now). Over the last 3 years we completed proof-of-principle studies and will further develop our software to include a module for DDIs prediction and an improved version for reactive metabolites prediction, as well as a generalized and more accurate force field (FF) based on chemical principles.